New treatments for Dupuytren contracture

D. Kay Kirkpatrick, MD, leads a roundtable discussion

Recently, the U.S. Food and Drug Administration (FDA) approved a new treatment for Dupuytren contracture—an enzyme injection (collagenase clostridium histolyticum) to soften and weaken the diseased cords of tissue that cause fingers to contract. In addition, other treatment options such as needle aponeurotomy—a minimally invasive technique that uses needles to puncture and weaken the contracting cords until they can be broken by mechanical force—are providing alternatives to surgery.

D. Kay Kirkpatrick, MD, a hand surgeon and member of the AAOS Practice Management Committee, recently conducted a roundtable discussion on these new treatments. Joining her were Charles Eaton, MD, FACS; F. Thomas D. Kaplan, MD; and Roy A. Meals, MD.

To View Full Article You Must